Venetoclax-proteasome inhibitor-dexamethasone for unfit patients with blastic plasmacytoid dendritic cell neoplasm.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

3 citing papers in PubMed.

1. Venetoclax in the Therapeutic Strategy for BPDCN Management.EJHaem · 2025
   Article
2. Real-world management of blastic plasmacytoid dendritic cell neoplasm at an academic center with a broad regional referral base.Leukemia research reports · 2025
   Article
3. Case Report: Early diagnostic precision matters: navigating therapeutic uncertainty in pediatric BPDCN illustrated by misdiagnosis sequelae and fleeting CAR-T response.Frontiers in pediatrics · 2025
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

16 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.